OptimizeRx (NASDAQ:OPRX) Price Target Cut to $13.00 by Analysts at B. Riley

OptimizeRx (NASDAQ:OPRX) had its price objective trimmed by B. Riley from $17.00 to $13.00 in a research note published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on the company. Barclays cut their price objective on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th. Stifel Nicolaus cut their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Royal Bank of Canada reduced their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Finally, JMP Securities reduced their price target on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and an average price target of $9.19.

OptimizeRx Stock Performance

Shares of OPRX opened at $5.17 on Tuesday. The company has a market capitalization of $95.24 million, a PE ratio of -3.89 and a beta of 1.34. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. OptimizeRx has a one year low of $3.78 and a one year high of $16.65. The company’s fifty day moving average price is $5.25 and its 200 day moving average price is $7.65.

Insider Activity

In other news, CEO William J. Febbo acquired 20,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets raised its position in OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares during the last quarter. Connors Investor Services Inc. raised its holdings in shares of OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after buying an additional 2,500 shares during the last quarter. Rhumbline Advisers lifted its position in OptimizeRx by 9.2% during the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock worth $315,000 after buying an additional 2,658 shares in the last quarter. Greenwood Capital Associates LLC grew its holdings in OptimizeRx by 8.0% during the 3rd quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after acquiring an additional 4,999 shares during the last quarter. Finally, Quest Partners LLC increased its position in OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after acquiring an additional 9,739 shares in the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.